Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647829 · ClinicalTrials.gov registry record · Phase 3
A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 197
- Enrollment target
NCT00647829 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 197 participants.
The verdict
NCT00647829, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 197 participants
- Enrollment target
Study Summary
The study was performed to evaluate the analgesic efficacy, safety, and tolerability of valdecoxib 20 mg twice daily (BID), valdecoxib 40 mg once daily (QD), and placebo in patients with moderately to severely painful symptomatic sore throat over a 24-hour period. In addition, the study was to validate a new scale and criteria for measuring pain in sore throat and evaluate the effects of selective serotonin reuptake inhibitors and past sore throat pain on pain score and efficacy of analgesics. The study also examined what type of medications are commonly used for sore throat and whether this information has relevance to analgesic efficacy.
Interventions
- DRUG placebo
- DRUG valdecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647829
The ClinicalTrials.gov registry entry for NCT00647829 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00647829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647829 about?
NCT00647829 is a clinical study titled "A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat". The study was performed to evaluate the analgesic efficacy, safety, and tolerability of valdecoxib 20 mg twice daily (BID), valdecoxib 40 mg once daily (QD), and placebo in patients with moderately to severely painful symptomatic sore throat over a 24-hour period. In addition, the study was to valid...
What is the current status of trial NCT00647829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 197 participants. The study started on 2003-02. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00647829?
The interventions under investigation include: placebo (DRUG), valdecoxib (DRUG).
Who is sponsoring clinical trial NCT00647829?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.